Sugi Predict

Sugi Predict / Targets / F2RL3

F2RL3

Proteinase-activated receptor 4 · Q96RI0 · F2RL3 on Sugi Atlas →

21,824 patent compounds predicted against F2RL3, 11,902 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL625574 SCHEMBL625574 0.65 20/20
SCHEMBL627245 SCHEMBL627245 0.50 20/20
SCHEMBL625515 SCHEMBL625515 0.50 15/20
SCHEMBL624845 SCHEMBL624845 0.52 13/20
SCHEMBL1943618 SCHEMBL1943618 0.51 13/20
SCHEMBL197784 SCHEMBL197784 0.51 13/20
SCHEMBL1944433 SCHEMBL1944433 0.62 12/20
SCHEMBL1945976 SCHEMBL1945976 0.61 12/20
SCHEMBL1946651 SCHEMBL1946651 0.64 11/20
SCHEMBL1944086 SCHEMBL1944086 0.51 11/20
SCHEMBL624077 SCHEMBL624077 0.50 11/20
SCHEMBL1944678 SCHEMBL1944678 0.41 11/20
SCHEMBL1671679 SCHEMBL1671679 0.38 11/20
SCHEMBL1947813 SCHEMBL1947813 0.63 10/20
SCHEMBL1943679 SCHEMBL1943679 0.62 10/20
SCHEMBL1946947 SCHEMBL1946947 0.60 10/20
SCHEMBL1946744 SCHEMBL1946744 0.44 10/20
SCHEMBL1672831 SCHEMBL1672831 0.39 10/20
SCHEMBL1672156 SCHEMBL1672156 0.34 10/20
SCHEMBL532634 SCHEMBL532634 0.53 9/20

Clinical trials — most relevant to F2RL3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Vorapaxar on Thrombin Generation and Coagulability PHASE4COMPLETED
Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases PHASE4COMPLETED
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor PHASE4COMPLETED
Effect of Sublingual Immunotherapy on Platlet factor4 Level in Children PHASE3UNKNOWN
suPAR to Guide Antibiotics in Emergency Department PHASE2/PHASE3UNKNOWN
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease PHASE2COMPLETED
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome PHASE1COMPLETED
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications PHASE1UNKNOWN
The Evaluation of Hemostasis in Hospitalized COVID-19 Patients nanUNKNOWN
SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome nanRECRUITING
Thrombin Regulated Platelet Activation nanCOMPLETED
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation nanCOMPLETED
PAR Regulation of Platelet Function in Diabetic Patients nanCOMPLETED
Impact of Combination of Clopidogrel With Aspirin on Postoperative Bleeding in Coronary Surgical Patients nanCOMPLETED
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery nanENROLLING_BY_INVITATION
The Severe Asthma Research Program III-Boston Clinical Site nanCOMPLETED
SuPAR in Adult Patients With Covid-19 nanCOMPLETED
Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Non-cardiac Surgery (SPARSE) nanCOMPLETED
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation nanUNKNOWN
Pathogenesis of Physical Induced Urticarial Syndromes nanCOMPLETED
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy nanCOMPLETED
Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia nanRECRUITING
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia nanCOMPLETED
The Prospective Risk Factor Evaluation & Discovery In CTEPH Study nanUNKNOWN
Genetic Association With Various Severities, Phenotypes and Endotypes of Asthma. nanRECRUITING
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications nanCOMPLETED
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD) nanCOMPLETED
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a F2RL3 binder may also engage these)

ProteinNameSimilarity
Q920E0 — 0.995 Q920E0 →
O88634 — 0.992 O88634 →
Q9JL21 — 0.976 Q9JL21 →
O00155 — 0.975 O00155 →
Q76JV1 — 0.975 Q76JV1 →
CCR10 C-C chemokine receptor type 10 0.973 landscape →
P2RY11 P2Y purinoceptor 11 0.973 landscape →
LPAR5 Lysophosphatidic acid receptor 5 0.973 landscape →
Q76JU9 — 0.972 Q76JU9 →
P0C5I1 — 0.971 P0C5I1 →
FFAR1 Free fatty acid receptor 1 0.971 landscape →
A0A6I8PUB9 — 0.971 A0A6I8PUB9 →
Q3ZC80 — 0.971 Q3ZC80 →
RXFP4 Relaxin-3 receptor 2 0.969 landscape →
Q8K3T4 — 0.968 Q8K3T4 →
Q76JU8 — 0.966 Q76JU8 →
O00270 — 0.963 O00270 →
Q149R9 — 0.961 Q149R9 →
FFAR3 Free fatty acid receptor 3 0.959 landscape →
Q99678 — 0.959 Q99678 →
Q924U0 — 0.958 Q924U0 →
Q9JJL9 — 0.958 Q9JJL9 →
GALR2 Galanin receptor type 2 0.958 landscape →
PTGDR2 Prostaglandin D2 receptor 2 0.957 landscape →
OXER1 Oxoeicosanoid receptor 1 0.956 landscape →
O15529 — 0.956 O15529 →
GALR3 Galanin receptor type 3 0.954 landscape →
Q5YA25 — 0.954 Q5YA25 →
Q86VZ1 — 0.953 Q86VZ1 →
LTB4R2 Leukotriene B4 receptor 2 0.953 landscape →